AR095593A1 - Agentes quelantes de precursores de producto final de glicación avanzada (age) - Google Patents
Agentes quelantes de precursores de producto final de glicación avanzada (age)Info
- Publication number
- AR095593A1 AR095593A1 ARP140101218A ARP140101218A AR095593A1 AR 095593 A1 AR095593 A1 AR 095593A1 AR P140101218 A ARP140101218 A AR P140101218A AR P140101218 A ARP140101218 A AR P140101218A AR 095593 A1 AR095593 A1 AR 095593A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- cooh
- integer
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Polymers & Plastics (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Los agentes quelantes de precursores de AGE comprenden aminas separadas por 2, 3 o 4 carbonos. Los agentes quelantes de precursores de AGE se pueden usar como agentes farmacéuticos y en composiciones farmacéuticas. Los agentes quelantes de precursores de AGE son particularmente útiles uniendo precursores AGE y dicarbonilos dietéticos en mamíferos en el tracto gastrointestinal para el tratamiento de enfermedades tales como nefropatía diabética, enfermedad renal crónica, aterosclerosis, apoplejía, cataratas, y enfermedad de Alzheimer. Reivindicación 1: Una composición farmacéutica que comprende un compuesto, en donde el compuesto comprende la estructura de fórmula (1) en donde: n es 0, 1 ó 2; o es 0, 1 ó 2; x es un número entero de 2 a 25.000; R¹ y R² son cada uno independientemente un grupo terminal farmacéuticamente aceptable, un polímero, o -Rˣ-polímero, en donde Rˣ se selecciona entre alquilo C₁₋₁₀, heteroalquilo C₂₋₉, cicloalquilo C₃₋₁₀, heterocicloalquilo C₂₋₉, arilo C₆₋₁₄, heteroarilo C₂₋₉, alquilamina C₁₋₁₀, -O(O)C-alquilo C₁₋₁₀, alquilo C₁₋₁₀-COOH, cicloalquilo C₃₋₁₀-COOH, -(O)CH₃, -OH, amida; R³ y R⁴ son cada uno independientemente H, un polímero, o -Rˣ-polímero, en donde Rˣ se selecciona entre alquilo C₁₋₁₀, heteroalquilo C₂₋₉, cicloalquilo C₃₋₁₀, heterocicloalquilo C₂₋₉, arilo C₆₋₁₄, heteroarilo C₂₋₉, alquilamina C₁₋₁₀, -O(O)C-alquilo C₁₋₁₀, alquilo C₁₋₁₀-COOH, cicloalquilo C₃₋₁₀-COOH, -(O)CH₃, -OH, amida; o si n es 0, R⁴ está ausente, y si o es 0, R³ está ausente; y R⁵ y R⁶ son cada uno independientemente H, alquilo C₁₋₁₀, heteroalquilo C₂₋₉, cicloalquilo C₃₋₁₀, heterocicloalquilo C₂₋₉, arilo C₆₋₁₄, heteroarilo C₂₋₉, alquilamina C₁₋₁₀, -O(O)C-alquilo C₁₋₁₀, alquilo C₁₋₁₀-COOH, cicloalquilo C₃₋₁₀-COOH, -(O)CH₃, -OH, -NH₂, -NH-alquilo C₁₋₁₀, -N[alquilo C₁₋₁₀)]₂ o R⁵ y R⁶ se toman en conjunto con los nitrógenos a los que están unidos para formar un anillo de 6 a 20 miembros. Reivindicación 2: La composición farmacéutica según la reivindicación 1, en donde R¹ y R² son cada uno independientemente: H, un grupo seleccionado entre alquilo C₁₋₁₀, heteroalquilo C₂₋₉, cicloalquilo C₃₋₁₀, heterocicloalquilo C₂₋₉, arilo C₆₋₁₄, heteroarilo C₂₋₉, alquilamina C₁₋₁₀, -O(O)C-alquilo C₁₋₁₀, alquilo C₁₋₁₀-COOH, cicloalquilo C₃₋₁₀-COOH, -(O)CH₃, -OH, amida, un grupo guanidino, representado con la fórmula (2), en donde a es un número entero de 0 a 25, un grupo cloruro de guanidinio, representado con la fórmula (3), en donde b es un número entero de 0 a 25, un grupo guanidinobenceno, representado con la fórmula (4), en donde c es un número entero de 0 a 25, un grupo dihidroxi, representado con la fórmula (5), en donde d es un número entero de 0 a 25, o un grupo polietilenglicol, representado con la fórmula (6) en donde e es un número entero de 1 a 400. Reivindicación 114: La composición farmacéutica según la reivindicación 113, en donde el polímero está reticulado con epiclorohidrina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792719P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095593A1 true AR095593A1 (es) | 2015-10-28 |
Family
ID=50439508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101218A AR095593A1 (es) | 2013-03-15 | 2014-03-17 | Agentes quelantes de precursores de producto final de glicación avanzada (age) |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160024233A1 (es) |
| EP (1) | EP2968403A1 (es) |
| JP (4) | JP2016512830A (es) |
| KR (1) | KR20150130492A (es) |
| CN (1) | CN105188718A (es) |
| AR (1) | AR095593A1 (es) |
| AU (2) | AU2014235500A1 (es) |
| BR (1) | BR112015023404A8 (es) |
| CA (1) | CA2906501A1 (es) |
| CL (1) | CL2015002624A1 (es) |
| CR (1) | CR20150545A (es) |
| DO (1) | DOP2015000221A (es) |
| EA (1) | EA201591733A1 (es) |
| HK (1) | HK1220607A1 (es) |
| IL (1) | IL241406A0 (es) |
| MA (1) | MA38487A1 (es) |
| MX (1) | MX2015012843A (es) |
| PE (1) | PE20151766A1 (es) |
| PH (1) | PH12015502019A1 (es) |
| SG (2) | SG11201506413PA (es) |
| TN (1) | TN2015000390A1 (es) |
| TW (1) | TW201521744A (es) |
| UY (1) | UY35441A (es) |
| WO (1) | WO2014150873A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41202A (fr) * | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| BR112020003638A2 (pt) * | 2017-08-31 | 2020-09-01 | Cytosorbents Corporation | redução de produtos finais de glicação avançada a partir de fluidos corporais |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985938A (en) * | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| PT1923064T (pt) * | 2001-04-18 | 2017-08-23 | Genzyme Corp | Utilização de um aminopolímero para reduzir a glicose sérica |
| WO2005032563A1 (en) * | 2003-09-02 | 2005-04-14 | Genzyme Corporation | Method for reducing vascular inflammation |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| EP1753861A4 (en) * | 2004-02-17 | 2010-03-10 | Dynamis Therapeutics Inc | FRUCTOSAMINE-3-KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN |
| FR2883873B1 (fr) * | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | Inhibiteurs d'age |
| CN105017481B (zh) * | 2010-02-24 | 2018-10-02 | 瑞立普萨公司 | 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺 |
-
2014
- 2014-03-12 MA MA38487A patent/MA38487A1/fr unknown
- 2014-03-12 KR KR1020157028860A patent/KR20150130492A/ko not_active Application Discontinuation
- 2014-03-12 PE PE2015001994A patent/PE20151766A1/es unknown
- 2014-03-12 EP EP14715503.0A patent/EP2968403A1/en active Pending
- 2014-03-12 AU AU2014235500A patent/AU2014235500A1/en not_active Abandoned
- 2014-03-12 WO PCT/US2014/024436 patent/WO2014150873A1/en active Application Filing
- 2014-03-12 SG SG11201506413PA patent/SG11201506413PA/en unknown
- 2014-03-12 SG SG10201707590XA patent/SG10201707590XA/en unknown
- 2014-03-12 JP JP2016501535A patent/JP2016512830A/ja active Pending
- 2014-03-12 US US14/776,059 patent/US20160024233A1/en not_active Abandoned
- 2014-03-12 BR BR112015023404A patent/BR112015023404A8/pt not_active Application Discontinuation
- 2014-03-12 CN CN201480026330.6A patent/CN105188718A/zh active Pending
- 2014-03-12 CA CA2906501A patent/CA2906501A1/en not_active Abandoned
- 2014-03-12 EA EA201591733A patent/EA201591733A1/ru unknown
- 2014-03-12 MX MX2015012843A patent/MX2015012843A/es unknown
- 2014-03-13 TW TW103108910A patent/TW201521744A/zh unknown
- 2014-03-14 UY UY0001035441A patent/UY35441A/es not_active Application Discontinuation
- 2014-03-17 AR ARP140101218A patent/AR095593A1/es unknown
-
2015
- 2015-09-04 TN TN2015000390A patent/TN2015000390A1/en unknown
- 2015-09-08 DO DO2015000221A patent/DOP2015000221A/es unknown
- 2015-09-09 IL IL241406A patent/IL241406A0/en unknown
- 2015-09-09 PH PH12015502019A patent/PH12015502019A1/en unknown
- 2015-09-11 CL CL2015002624A patent/CL2015002624A1/es unknown
- 2015-10-13 CR CR20150545A patent/CR20150545A/es unknown
-
2016
- 2016-07-20 HK HK16108617.8A patent/HK1220607A1/zh unknown
-
2017
- 2017-12-14 US US15/842,177 patent/US20180265613A1/en not_active Abandoned
-
2018
- 2018-04-25 JP JP2018083623A patent/JP2018135365A/ja active Pending
-
2019
- 2019-02-22 AU AU2019201259A patent/AU2019201259A1/en not_active Abandoned
- 2019-12-06 JP JP2019220818A patent/JP2020055850A/ja active Pending
-
2021
- 2021-12-17 JP JP2021204770A patent/JP2022037143A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201506413PA (en) | 2015-09-29 |
| CN105188718A (zh) | 2015-12-23 |
| TN2015000390A1 (en) | 2017-01-03 |
| JP2018135365A (ja) | 2018-08-30 |
| CL2015002624A1 (es) | 2016-03-11 |
| US20180265613A1 (en) | 2018-09-20 |
| SG10201707590XA (en) | 2017-11-29 |
| UY35441A (es) | 2014-10-31 |
| JP2016512830A (ja) | 2016-05-09 |
| KR20150130492A (ko) | 2015-11-23 |
| IL241406A0 (en) | 2015-11-30 |
| US20160024233A1 (en) | 2016-01-28 |
| MA38487A1 (fr) | 2017-12-29 |
| MX2015012843A (es) | 2016-08-08 |
| EA201591733A1 (ru) | 2016-01-29 |
| EP2968403A1 (en) | 2016-01-20 |
| JP2020055850A (ja) | 2020-04-09 |
| HK1220607A1 (zh) | 2017-05-12 |
| JP2022037143A (ja) | 2022-03-08 |
| BR112015023404A2 (pt) | 2017-07-18 |
| CA2906501A1 (en) | 2014-09-25 |
| CR20150545A (es) | 2015-12-01 |
| WO2014150873A1 (en) | 2014-09-25 |
| AU2019201259A1 (en) | 2019-03-14 |
| PE20151766A1 (es) | 2015-12-11 |
| TW201521744A (zh) | 2015-06-16 |
| PH12015502019A1 (en) | 2016-01-11 |
| DOP2015000221A (es) | 2015-12-15 |
| AU2014235500A1 (en) | 2015-11-05 |
| BR112015023404A8 (pt) | 2019-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094668A1 (es) | Amidas como moduladores de canales de sodio | |
| WO2016134301A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP2015537020A5 (es) | ||
| AR091857A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| WO2015010054A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP2013523763A5 (es) | ||
| EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
| AR091858A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| JP2013521312A5 (es) | ||
| PH12015500465A1 (en) | Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof | |
| JP2013032389A5 (es) | ||
| EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
| WO2013188792A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP2014508753A5 (es) | ||
| RU2013142448A (ru) | Новые сульфонаминохинолиновые антагонисты гепсидина | |
| EA201790661A2 (ru) | Ингибиторы вируса гепатита c | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| UY32174A (es) | Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones | |
| JP2017511321A5 (es) | ||
| EA201401150A1 (ru) | Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств | |
| EA201190320A1 (ru) | Гетероциклические сульфонамиды, их применения и фармацевтические композиции | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR095366A1 (es) | Poliamidas funcionales de amina | |
| CY1111442T1 (el) | Ενωσεις πιπεριδινης και χρησεις αυτων | |
| PE20190328A1 (es) | Compuestos de carfilzomib pegilados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |